| Q28486089 | A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer |
| Q34262817 | A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies |
| Q36345737 | ADPKD: molecular characterization and quest for treatment |
| Q37144740 | Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer |
| Q91714264 | CDKN2a/p16 Antagonizes Hepatic Stellate Cell Activation and Liver Fibrosis by Modulating ROS Levels |
| Q36661722 | Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer |
| Q45094689 | Ciglitizone inhibits cell proliferation in human uterine leiomyoma via activation of store-operated Ca2+ channels |
| Q35101709 | Coffee component hydroxyl hydroquinone (HHQ) as a putative ligand for PPAR gamma and implications in breast cancer |
| Q36499766 | DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents |
| Q59282175 | Differential Regulation of Vascular Endothelial Growth Factor Expression by Peroxisome Proliferator-activated Receptors in Bladder Cancer Cells |
| Q40201153 | Effect of ligand troglitazone on peroxisome proliferator-activated receptor gamma expression and cellular growth in human colon cancer cells |
| Q36210174 | Effects of PPARgamma and combined agonists on the urinary tract of rats and other species |
| Q44375640 | Effects of thiazolidinedione in patients with active bladder cancer |
| Q35745965 | Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas |
| Q40152607 | Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival. |
| Q37375400 | Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer |
| Q46578441 | Heat shock proteins: new keys to the development of cytoprotective therapies |
| Q39177047 | Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion |
| Q38848728 | Identification of novel potential genetic predictors of urothelial bladder carcinoma susceptibility in Pakistani population. |
| Q40262195 | Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties. |
| Q44490328 | Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide |
| Q41965458 | Investigations on Binding Pattern of Kinase Inhibitors with PPARγ: Molecular Docking, Molecular Dynamic Simulations, and Free Energy Calculation Studies. |
| Q44700024 | Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas |
| Q46393805 | Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma |
| Q38329996 | Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas |
| Q39660411 | Mistletoe lectin‐I augments antiproliferative effects of the PPARγ agonist rosiglitazone on human malignant melanoma cells |
| Q34602968 | Natural ligands of PPARgamma: are prostaglandin J(2) derivatives really playing the part? |
| Q39272833 | New insights into antidiabetic drugs: Possible applications in cancer treatment. |
| Q40343222 | Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. |
| Q28066756 | PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs |
| Q37165190 | PPAR Ligands for Cancer Chemoprevention |
| Q34089258 | PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study |
| Q36742811 | PPARgamma and Apoptosis in Cancer |
| Q46825357 | PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway |
| Q33235601 | PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma |
| Q34863027 | PPARgamma-regulated tight junction development during human urothelial cytodifferentiation |
| Q37719276 | PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors |
| Q39502492 | PPARγ disease gene network and identification of therapeutic targets for prostate cancer |
| Q37607679 | Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use |
| Q34568687 | Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review |
| Q28366616 | Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma |
| Q33215831 | Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines |
| Q43796622 | Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature |
| Q55079635 | Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. |
| Q36013549 | Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study |
| Q28580246 | Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats |
| Q36795404 | Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer |
| Q34628009 | Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. |
| Q37583052 | Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study. |
| Q39551235 | Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line |
| Q38122640 | Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn? |
| Q26771960 | Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor |
| Q45926666 | Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels. |
| Q34646050 | Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer |
| Q40769938 | Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways |
| Q37165194 | The Critical Role of PPARgamma in Human Malignant Melanoma |
| Q42231195 | The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPARγ-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells. |
| Q21342955 | The Role of PPARs in Cancer |
| Q28478349 | The antidiabetic drug ciglitazone induces high grade bladder cancer cells apoptosis through the up-regulation of TRAIL |
| Q38357506 | The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. |
| Q77753218 | The role of peroxisome proliferator-activated receptor gamma in bladder cancer in relation to angiogenesis and progression |
| Q36328530 | The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). |
| Q36001145 | The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study |
| Q39239818 | Thermodynamics in cancers: opposing interactions between PPAR gamma and the canonical WNT/beta-catenin pathway |
| Q38641190 | Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future |
| Q40633862 | Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma |
| Q43938006 | Troglitazione affects survival of human osteosarcoma cells |
| Q95721208 | Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats |
| Q41894503 | Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours |
| Q35466765 | Use of noninsulin anti diabetics for prevention and treatment of cancer- narrative review article |
| Q84968395 | Vitamin C deficiency accelerates bone loss inducing an increase in PPAR-γ expression in SMP30 knockout mice |
| Q43159399 | Vitamin C deficiency attenuates liver fibrosis by way of up-regulated peroxisome proliferator-activated receptor-gamma expression in senescence marker protein 30 knockout mice |
| Q24806395 | A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor li |